Skip to main content
DNTH
NASDAQ Life Sciences

Dianthus CEO・主見発用者 民用所有相似股掌

feedReported by Wiseek News
Sentiment info
Negative
Importance info
8
Price
$77.8
Mkt Cap
$3.463B
52W Low
$13.365
52W High
$88.02
Market data snapshot near publication time

summarizeSummary

Dianthus Therapeutics的CEO和公行帮一、主資計会員、和EVP和Head of R⛝通歡三亲中消一、改面市倭の公行股掌を「2026年3月前12日」に終件了。比较、三亲の中消一、追加「Rule 10b5-1」の一般用認用詞等管理プランに以て、公行股掌の終件を完了。歡消事件は、公司が$400 million」の点大化公行生成を完了しなく、終件に影響して満された。一般用認用詞等管理プラン中で実行されたが、主見発用者を含れた公司の追加相似股掌を完了民用するたる、一般、公司の本当に对すずる追动幸定性の中消について、前弹の股用者の性が影響されたる。

この発表時点で、DNTHは$77.80で取引されており、市場はNASDAQ、セクターはLife Sciences、時価総額は約$34.6億でした。 52週の取引レンジは$13.37から$88.02でした。 このニュースはネガティブの市場センチメント、重要度スコア8/10と評価されました。 出典：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed DNTH - Latest Insights

DNTH
Mar 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Dianthus Therapeutics Secures $676M in Offering, Receives Favorable FDA Feedback for Claseprubart Trials
Sentiment: Positive
View Wiseek Article
DNTH
Mar 13, 2026, 8:40 PM EDT
Source: Wiseek News
Importance Score:
8
Dianthus CEO, Key Executives Liquidate All Direct Stock Holdings
Sentiment: Negative
View Wiseek Article
DNTH
Mar 12, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Dianthus Therapeutics Finalizes $673.5M Upsized Public Offering, Including Full Underwriter Option Exercise
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 11, 2026, 5:28 PM EDT
Filing Type: 424B5
Importance Score:
8
Dianthus Therapeutics Prices $625M Public Offering at $81.00 Per Share, Extending Cash Runway
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 10, 2026, 10:56 PM EDT
Source: Reuters
Importance Score:
8
Dianthus Therapeutics Prices Upsized $625M Offering at $81/Share
Sentiment: Negative
View Wiseek Article
DNTH
Mar 10, 2026, 9:54 PM EDT
Filing Type: S-3MEF
Importance Score:
8
Dianthus Therapeutics Upsizes Shelf Registration by $120M, Increasing Capital Raise Capacity to $720M
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 09, 2026, 5:25 PM EDT
Filing Type: 424B5
Importance Score:
9
Dianthus Therapeutics Details Proposed $400M Public Offering Following Positive Phase 3 Trial Results
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dianthus Therapeutics Commences $400M Public Offering Following Positive Phase 3 Trial News
Sentiment: Negative
View Wiseek Article
DNTH
Mar 09, 2026, 7:21 AM EDT
Filing Type: 10-K
Importance Score:
9
Dianthus Therapeutics Reports Early Phase 3 Success for Claseprubart in CIDP, Extends Cash Runway
Sentiment: Positive
View Wiseek Article
DNTH
Mar 09, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
9
Dianthus Therapeutics Achieves Early GO Decision in Pivotal Phase 3 CIDP Trial for Claseprubart
Sentiment: Positive
View Wiseek Article